Study S000168

The Safety, Preliminary Pharmacodynamics and Pharmacokinetics Study of rExenatide-4 in Chinese T2DM

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01342042
Acronym: SPPS
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: NONE
Status: UNKNOWN
Enrollment: 36
Start: 2011-03
Primary completion: 2011-12
Lead sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions: Type 2 Diabetes
Interventions: BIOLOGICAL:rExenatide-4
Results posted: FALSE

Registered primary outcomes

To compare treatment arms in terms of change from baseline to endpoint in HbA1c [12 Weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0011151	Pharmacokinetics and Preliminary Pharmacodynamics of Single- and Multiple-dose Lyophilized Recombinant Glucagon-like Peptide-1 Receptor Agonist (rE-4) in Chinese Patients with Type 2 Diabetes Mellitus. Wang Y, Clinical drug investigation	2017	Randomized trial	PMID 28932995 DOI	cites ClinicalTrials.gov:NCT01342042; registry reference DERIVED:28932995